Report Overview

Indian Paediatric Glioma therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.

Paediatric brain tumor is uncontrolled or abnormal growth of normal cell in the brain in children. Brain tumors mainly are of two types, cancerous (malignant) and noncancerous (benign). It is second most common type of cancer in children and it comprise about 25% of childhood cancer. The incidence of central nervous system (CNS) tumors in India ranges from 5 to 10 per 100,000 population with an increasing trend and accounts for 2% of malignancies. The development of a promising drug to treat Glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years. Brain tumour is a cancerous or a non-cancerous mass of growth of abnormal cells in the brain and is a leading cause of death in India. Shockingly, it is on the rise in the age group of 3-15 years, where the chances of survival are also less. Every year over 2,500 of the Indian children suffer from medulloblastoma, a paediatric malignant primary brain tumour. The average survival time is 12-18 months - only 25% of glioblastoma patients survive more than one year, and only 5% of patients survive more than five years. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs.



Market Driving Factors:

The driving factors in the growth of the Paediatric Glioma therapeutics market include Incurable Status of the Disease, increase in the Aging Population, and increasing prevalence of brain disorders. A persons risk of developing Paediatric Glioma depends on many factors, including age, genetics, and exposure to risk factors. Growth in the Glioma therapeutics market can also be attributed to patients constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment.